Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort.

Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort.

Oral anticoagulant (OAC) therapy has been the main treatment approach for stroke prevention for decades. Warfarin is the most widely prescribed OAC in the United States, but is difficult to manage due to variability in dose requirements across individuals. Pharmacogenomics may mitigate risk concerns...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristi M Swanson, Ye Zhu, Ricardo L Rojas, Jennifer L St Sauver, Suzette J Bielinski, Debra J Jacobsen, Sue L Visscher, Liewei Wang, Richard Weinshilboum, Bijan J Borah
Formato: Artículo
Lenguaje:English
Publicado: Public Library of Science (PLoS) 2020-01-01
Colección:PLoS ONE
Acceso en línea:https://doi.org/10.1371/journal.pone.0233316

Internet

https://doi.org/10.1371/journal.pone.0233316

Ejemplares similares